Allspring Global Investments Holdings LLC Grows Stock Holdings in argenex SE (NASDAQ:ARGX)

Allspring Global Investments Holdings LLC raised its stake in argenex SE (NASDAQ:ARGX - Free Report) by 22.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 176,450 shares of the company's stock after buying an additional 32,239 shares during the period. Allspring Global Investments Holdings LLC owned about 0.29% of argenex worth $100,063,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in the stock. FMR LLC boosted its position in argenex by 17.2% in the 4th quarter. FMR LLC now owns 5,618,222 shares of the company's stock valued at $3,455,207,000 after buying an additional 824,750 shares during the period. Capital World Investors boosted its position in argenex by 5.1% in the 4th quarter. Capital World Investors now owns 1,786,936 shares of the company's stock valued at $1,099,002,000 after buying an additional 86,687 shares during the period. RTW Investments LP boosted its position in argenex by 2.9% in the 4th quarter. RTW Investments LP now owns 673,497 shares of the company's stock valued at $414,201,000 after buying an additional 19,067 shares during the period. Clearbridge Investments LLC boosted its position in argenex by 6.8% in the 4th quarter. Clearbridge Investments LLC now owns 629,828 shares of the company's stock valued at $387,344,000 after buying an additional 40,330 shares during the period. Finally, Lord Abbett & CO. LLC lifted its position in shares of argenex by 26.5% in the 4th quarter. Lord Abbett & CO. LLC now owns 206,202 shares of the company's stock worth $126,814,000 after purchasing an additional 43,239 shares during the period. 60.32% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ARGX has been the subject of several research reports. Sanford C. Bernstein raised shares of argenex from a "market perform" rating to an "outperform" rating in a research report on Monday, March 17th. JMP Securities set a $699.00 price target on shares of argenex in a research report on Wednesday, May 14th. HC Wainwright reaffirmed a "buy" rating and issued a $720.00 price target on shares of argenex in a research report on Tuesday, June 10th. Baird R W raised shares of argenex from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, May 13th. Finally, Oppenheimer upped their price target on shares of argenex from $704.00 to $708.00 and gave the stock an "outperform" rating in a research report on Friday, May 9th. One investment analyst has rated the stock with a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $729.93.

argenex Stock Up 0.0%

NASDAQ:ARGX opened at $560.14 on Friday. argenex SE has a 52 week low of $428.97 and a 52 week high of $678.21. The firm has a 50 day moving average of $581.58 and a 200 day moving average of $607.07. The stock has a market capitalization of $34.20 billion, a price-to-earnings ratio of 34.56, a PEG ratio of 1.01 and a beta of 0.39.

argenex (NASDAQ:ARGX - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $2.58 EPS for the quarter, beating analysts' consensus estimates of $2.32 by $0.26. argenex had a net margin of 40.20% and a return on equity of 16.15%. The company had revenue of $1.35 billion during the quarter, compared to analysts' expectations of $748.34 million. As a group, analysts expect that argenex SE will post 3.13 EPS for the current year.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenex SE (NASDAQ:ARGX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.